MX358494B - Derivado de acido pirrolidin-3-ilacetico. - Google Patents
Derivado de acido pirrolidin-3-ilacetico.Info
- Publication number
- MX358494B MX358494B MX2014002210A MX2014002210A MX358494B MX 358494 B MX358494 B MX 358494B MX 2014002210 A MX2014002210 A MX 2014002210A MX 2014002210 A MX2014002210 A MX 2014002210A MX 358494 B MX358494 B MX 358494B
- Authority
- MX
- Mexico
- Prior art keywords
- group
- substituted groups
- groups
- substituted
- unsubstituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
Un compuesto representado por la fórmula (1) o una sal farmacéuticamente aceptable del mismo que tiene un efecto inhibidor en la ruta de fractalcina-CX3CR1: (ver Fórmula) en la que R representa un grupo alquilo de C1-6 no sustituido o que tiene 1 a 3 sustituyentes seleccionados del Grupo A de Sustituyentes, un grupo cicloalquilo de C3-8 no sustituido o que tiene 1 a 3 sustituyentes seleccionados del Grupo A de Sustituyentes, o un grupo cicloalquenilo de C3-8 no sustituido o que tiene 1 a 3 sustituyentes seleccionados del Grupo A de Sustituyentes, X representa un grupo alquilo de C1-6, Y y Z son iguales o diferentes entre sí, y cada uno representa un átomo de halógeno o un grupo alquilo de C1-6 no sustituido o que tiene 1 a 3 sustituyentes seleccionados del Grupo B de Sustituyentes, n representa 0 ó 1, el Grupo A de Sustituyentes consiste en átomos de halógeno, y el Grupo B de Sustituyentes consiste en átomos de halógeno.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011199482 | 2011-09-13 | ||
| PCT/JP2012/073171 WO2013039057A1 (ja) | 2011-09-13 | 2012-09-11 | ピロリジン－３－イル酢酸誘導体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014002210A MX2014002210A (es) | 2014-04-30 |
| MX358494B true MX358494B (es) | 2018-08-23 |
Family
ID=47883287
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014002210A MX358494B (es) | 2011-09-13 | 2012-09-11 | Derivado de acido pirrolidin-3-ilacetico. |
Country Status (32)
| Country | Link |
|---|---|
| EP (1) | EP2757103B1 (es) |
| JP (1) | JP5829689B2 (es) |
| KR (1) | KR101963922B1 (es) |
| CN (1) | CN103764648B (es) |
| AR (1) | AR087788A1 (es) |
| AU (1) | AU2012309556B2 (es) |
| BR (1) | BR112014004267B1 (es) |
| CA (1) | CA2844617C (es) |
| CL (1) | CL2014000484A1 (es) |
| CY (1) | CY1117460T1 (es) |
| DK (1) | DK2757103T3 (es) |
| ES (1) | ES2564732T3 (es) |
| HK (1) | HK1193407A1 (es) |
| HR (1) | HRP20160166T1 (es) |
| HU (1) | HUE026824T2 (es) |
| IL (1) | IL230804A (es) |
| JO (1) | JO3082B1 (es) |
| ME (1) | ME02383B (es) |
| MX (1) | MX358494B (es) |
| MY (1) | MY169869A (es) |
| PE (1) | PE20141353A1 (es) |
| PL (1) | PL2757103T3 (es) |
| PT (1) | PT2757103E (es) |
| RS (1) | RS54582B1 (es) |
| RU (1) | RU2615135C2 (es) |
| SG (1) | SG11201400163WA (es) |
| SI (1) | SI2757103T1 (es) |
| SM (1) | SMT201600071B (es) |
| TW (1) | TWI543975B (es) |
| UA (1) | UA112873C2 (es) |
| WO (1) | WO2013039057A1 (es) |
| ZA (1) | ZA201400918B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2975035B1 (en) * | 2013-03-12 | 2017-08-02 | Eisai R&D Management Co., Ltd. | Salt of pyrrolidin-3-yl acetic acid derivative and crystals thereof |
| WO2014142086A1 (ja) * | 2013-03-13 | 2014-09-18 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ピロリジン－３－イル酢酸誘導体およびピペリジン－３－イル酢酸誘導体 |
| WO2024083933A1 (en) | 2022-10-19 | 2024-04-25 | Astrazeneca Ab | 2,4,6-trisubstituted 1,3,5-triazines as modulators of cx 3cr1 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4263391B2 (ja) | 2001-03-19 | 2009-05-13 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 抗ｃｘ３ｃｒ１抗体、抗フラクタルカイン抗体及びフラクタルカインの利用 |
| AU2002363236A1 (en) * | 2001-10-30 | 2003-05-12 | Millennium Pharmaceuticals, Inc. | Compounds, pharmaceutical compositions and methods of use therefor |
| US20070142386A1 (en) * | 2003-10-07 | 2007-06-21 | Astrazeneca | New 2-substituted, 4-amino-thiazolo[4,5-d] pyrimidines, useful as chemokine receptor antagonists, esp. cx3cr1 |
| UA90707C2 (en) | 2005-04-06 | 2010-05-25 | Астразенека Аб | Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives |
| AR053347A1 (es) | 2005-04-06 | 2007-05-02 | Astrazeneca Ab | Derivados de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona 5,7-sustituidos |
| TW200820973A (en) | 2006-09-29 | 2008-05-16 | Astrazeneca Ab | Novel compounds 480 |
| NZ576519A (en) | 2006-09-29 | 2011-11-25 | Astrazeneca Ab | Novel 5,7-disubstituted [1, 3] thiazolo [4, 5-d] pyrimidin-2 (3h)-amine derivatives and their use in therapy |
| US20100210633A1 (en) * | 2006-10-12 | 2010-08-19 | Epix Delaware, Inc. | Carboxamide compounds and their use |
| EP2262777B8 (en) * | 2008-03-07 | 2016-05-04 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A. | 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1 and cx3cr1 |
| AR071036A1 (es) | 2008-03-26 | 2010-05-19 | Astrazeneca Ab | Derivados 5, 7-disustituidos de [1, 3]tiazolo[4, 5-d]pirimidin-2 (3h)-ona, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por el receptor cx3cr1. |
-
2012
- 2012-09-05 JO JOP/2012/0251A patent/JO3082B1/ar active
- 2012-09-05 TW TW101132401A patent/TWI543975B/zh active
- 2012-09-06 AR ARP120103280A patent/AR087788A1/es active IP Right Grant
- 2012-09-11 MX MX2014002210A patent/MX358494B/es active IP Right Grant
- 2012-09-11 JP JP2013533669A patent/JP5829689B2/ja active Active
- 2012-09-11 RU RU2014107536A patent/RU2615135C2/ru active
- 2012-09-11 MY MYPI2014700213A patent/MY169869A/en unknown
- 2012-09-11 RS RS20160106A patent/RS54582B1/en unknown
- 2012-09-11 CN CN201280041634.0A patent/CN103764648B/zh active Active
- 2012-09-11 CA CA2844617A patent/CA2844617C/en active Active
- 2012-09-11 ME MEP-2016-37A patent/ME02383B/me unknown
- 2012-09-11 HU HUE12831085A patent/HUE026824T2/en unknown
- 2012-09-11 WO PCT/JP2012/073171 patent/WO2013039057A1/ja active Application Filing
- 2012-09-11 AU AU2012309556A patent/AU2012309556B2/en not_active Ceased
- 2012-09-11 SG SG11201400163WA patent/SG11201400163WA/en unknown
- 2012-09-11 SI SI201230463T patent/SI2757103T1/sl unknown
- 2012-09-11 ES ES12831085.1T patent/ES2564732T3/es active Active
- 2012-09-11 KR KR1020147003630A patent/KR101963922B1/ko active IP Right Grant
- 2012-09-11 PE PE2014000266A patent/PE20141353A1/es active IP Right Grant
- 2012-09-11 PT PT128310851T patent/PT2757103E/pt unknown
- 2012-09-11 PL PL12831085T patent/PL2757103T3/pl unknown
- 2012-09-11 EP EP12831085.1A patent/EP2757103B1/en active Active
- 2012-09-11 DK DK12831085.1T patent/DK2757103T3/en active
- 2012-09-11 BR BR112014004267-5A patent/BR112014004267B1/pt active IP Right Grant
- 2012-11-09 UA UAA201401661A patent/UA112873C2/uk unknown
-
2014
- 2014-02-03 IL IL230804A patent/IL230804A/en active IP Right Grant
- 2014-02-06 ZA ZA2014/00918A patent/ZA201400918B/en unknown
- 2014-02-27 CL CL2014000484A patent/CL2014000484A1/es unknown
- 2014-07-04 HK HK14106800.1A patent/HK1193407A1/xx not_active IP Right Cessation
-
2016
- 2016-02-16 HR HRP20160166TT patent/HRP20160166T1/hr unknown
- 2016-03-10 SM SM201600071T patent/SMT201600071B/xx unknown
- 2016-03-16 CY CY20161100224T patent/CY1117460T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021008356A (es) | Inhibidores de jak2 y alk2 y metodos para su uso. | |
| MX357021B (es) | Derivados de imidazo[1,2-b]piridazina como inhibidores de cinasa. | |
| MY168201A (en) | Agricultural And Horticultural Fungicidal Composition | |
| SG11201805286RA (en) | α,β-UNSATURATED AMIDE COMPOUND | |
| MX2014000452A (es) | Derivados de azabencimiazol que tiene actividad activadora de la proteina cinasa activada monofosfato de denosina (ampk). | |
| MX2013011551A (es) | Compuestos y derivados hetero - biciclicos n - sustituidos para combatir las pestes en animales. | |
| WO2012122011A3 (en) | Amino-quinolines as kinase inhibitors | |
| MX347562B (es) | Derivados fungicidas de 3-fenil[(heterociclilmetoxi)imino]metil}-1 ,2,4-oxadiazol-5(4h)-ona sustituidos en 4. | |
| MX348228B (es) | Cristal de derivados de 6,7-insaturado-7-carbamoil morfinano y metodo para producir el mismo. | |
| WO2012101011A3 (en) | New aryl-benzocycloalkyl amide derivatives | |
| MX2013008162A (es) | Inhibidores de pirimidina y topoisomerasa iv. | |
| EA201391325A1 (ru) | Новые производные цефалоспорина и их фармацевтические композиции | |
| MX2013007938A (es) | Compuesto biciclico novedoso o sal del mismo. | |
| IN2014CN04449A (es) | ||
| WO2013177534A3 (en) | New salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof | |
| UA110128C2 (uk) | Індолкарбоксаміди та бензімідазолкарбоксаміди як інсектициди та акарициди | |
| PH12014502492A1 (en) | Pyrazole compounds as sglt1 inhibitors | |
| WO2011159124A3 (ko) | Ｉｎｔｅｒｌｅｕｋｉｎ-６ 억제 작용을 갖는 신규한 벤즈옥사졸 유도체, 이의 제조 방법 및 이를 포함하는 약학적 조성물 | |
| MX358494B (es) | Derivado de acido pirrolidin-3-ilacetico. | |
| UA111950C2 (uk) | Гетероциклічні сполуки для лікування або профілактики розладів, викликаних зниженою нейротрансмісією серотоніну, норепінефрину або допаміну | |
| MX2013009386A (es) | Nuevos compuestos de azaespirodecanona. | |
| MX355654B (es) | Derivado de paroxetina. | |
| WO2013062332A3 (ko) | 시링가레시놀을 포함하는 혈관 노화 억제용 조성물 | |
| WO2013098837A3 (en) | A bis-quinaldine compound and a process for preparing the same | |
| MY186396A (en) | Xanthine derivative |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |